Heng Luo

Heng Luo


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYing Yu
Ying Yu
JFJames C. Fuscoe
James C. Fuscoe
CZChen Zhao
Chen Zhao
CGChao Guo
Chao Guo
MJMeiwen Jia
Meiwen Jia
CWCharles Wang
Charles Wang
The rat has been used extensively as a model for evaluating chemical toxicities and for understanding drug mechanisms. However, its transcriptome across multiple organs, or developmental stages, has not yet been reported. Here we show, as part of the SEQC consortium efforts, a comprehensive rat transcriptomic BodyMap created by performing RNA-Seq on 320 samples from 11 organs of both sexes of juvenile, adolescent, adult and aged Fischer 344 rats. We catalogue the expression profiles of 40,064 genes, 65,167 transcripts, 31,909 alternatively spliced transcript variants and 2,367 non-coding genes/non-coding RNAs (ncRNAs) annotated in AceView. We find that organ-enriched, differentially expressed genes reflect the known organ-specific biological activities. A large number of transcripts show organ-specific, age-dependent or sex-specific differential expression patterns. We create a web-based, open-access rat BodyMap database of expression profiles with crosslinks to other widely used databases, anticipating that it will serve as a primary resource for biomedical research using the rat model.

25 June 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
WZWenqian Zhang
Wenqian Zhang
YYYing Yu
Ying Yu
FHFalk Hertwig
Falk Hertwig
JTJean Thierry-Mieg
Jean Thierry-Mieg
WZWenwei Zhang
Wenwei Zhang
MFMatthias Fischer
Matthias Fischer
Background: Gene expression profiling is being widely applied in cancer research to identify biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for transcriptome-based applications beyond the limitations of microarrays, we sought to systematically evaluate the performance of RNA-seq-based and microarray-based classifiers in this MAQC-III/SEQC study for clinical endpoint prediction using neuroblastoma as a model. Results: We generate gene expression profiles from 498 primary neuroblastomas using both RNA-seq and 44 k microarrays. Characterization of the neuroblastoma transcriptome by RNA-seq reveals that more than 48,000 genes and 200,000 transcripts are being expressed in this malignancy. We also find that RNA-seq provides much more detailed information on specific transcript expression patterns in clinico-genetic neuroblastoma subgroups than microarrays. To systematically compare the power of RNA-seq and microarray-based models in predicting clinical endpoints, we divide the cohort randomly into training and validation sets and develop 360 predictive models on six clinical endpoints of varying predictability. Evaluation of factors potentially affecting model performances reveals that prediction accuracies are most strongly influenced by the nature of the clinical endpoint, whereas technological platforms (RNA-seq vs. microarrays), RNA-seq data analysis pipelines, and feature levels (gene vs. transcript vs. exon-junction level) do not significantly affect performances of the models. Conclusions: We demonstrate that RNA-seq outperforms microarrays in determining the transcriptomic characteristics of cancer, while RNA-seq and microarray-based models perform similarly in clinical endpoint prediction. Our findings may be valuable to guide future studies on the development of gene expression-based predictive models and their implementation in clinical practice.

10 May 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HLHeng Luo
Heng Luo
JCJian Chen
Jian Chen
LSLeming Shi
Leming Shi
MMMike Mikailov
Mike Mikailov
HZHuang Zhu
Huang Zhu
LYLun Yang
Lun Yang
Identifying new indications for existing drugs (drug repositioning) is an efficient way of maximizing their potential. Adverse drug reaction (ADR) is one of the leading causes of death among hospitalized patients. As both new indications and ADRs are caused by unexpected chemical–protein interactions on off-targets, it is reasonable to predict these interactions by mining the chemical–protein interactome (CPI). Making such predictions has recently been facilitated by a web server named DRAR-CPI. This server has a representative collection of drug molecules and targetable human proteins built up from our work in drug repositioning and ADR. When a user submits a molecule, the server will give the positive or negative association scores between the user’s molecule and our library drugs based on their interaction profiles towards the targets. Users can thus predict the indications or ADRs of their molecule based on the association scores towards our library drugs. We have matched our predictions of drug–drug associations with those predicted via gene-expression profiles, achieving a matching rate as high as 74%. We have also successfully predicted the connections between anti-psychotics and anti-infectives, indicating the underlying relevance of anti-psychotics in the potential treatment of infections, vice versa. This server is freely available at http://cpi.bio-x.cn/drar/ .

1 July 2018
Verified
Conference Paper
Closed access
KGKyle Yingkai Gao
Kyle Yingkai Gao
AFAchille Fokoue
Achille Fokoue
HLHeng Luo
Heng Luo
AIArun Iyengar
Arun Iyengar
SDSanjoy Dey
Sanjoy Dey
PZPing Zhang
Ping Zhang
The identification of drug-target interactions (DTIs) is a key task in drug discovery, where drugs are chemical compounds and targets are proteins. Traditional DTI prediction methods are either time consuming (simulation-based methods) or heavily dependent on domain expertise (similarity-based and feature-based methods). In this work, we propose an end-to-end neural network model that predicts DTIs directly from low level representations. In addition to making predictions, our model provides biological interpretation using two-way attention mechanism. Instead of using simplified settings where a dataset is evaluated as a whole, we designed an evaluation dataset from BindingDB following more realistic settings where predictions of unobserved examples (proteins and drugs) have to be made. We experimentally compared our model with matrix factorization, similarity-based methods, and a previous deep learning approach. Overall, the results show that our model outperforms other approaches without requiring domain knowledge and feature engineering. In a case study, we illustrated the ability of our approach to provide biological insights to interpret the predictions.

20 February 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JMJoseph A. Morrone
Joseph A. Morrone
JWJeffrey K. Weber
Jeffrey K. Weber
THTien Huynh
Tien Huynh
HLHeng Luo
Heng Luo
WCWendy D. Cornell
Wendy D. Cornell

31 March 2011 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
LYLun Yang
Lun Yang
KWKejian Wang
Kejian Wang
JCJian Chen
Jian Chen
AJAnil G Jegga
Anil G Jegga
HLHeng Luo
Heng Luo
LHLin He
Lin He
In the era of personalized medical practice, understanding the genetic basis of patient-specific adverse drug reaction (ADR) is a major challenge. Clozapine provides effective treatments for schizophrenia but its usage is limited because of life-threatening agranulocytosis. A recent high impact study showed the necessity of moving clozapine to a first line drug, thus identifying the biomarkers for drug-induced agranulocytosis has become important. Here we report a methodology termed as antithesis chemical-protein interactome (CPI), which utilizes the docking method to mimic the differences in the drug-protein interactions across a panel of human proteins. Using this method, we identified HSPA1A, a known susceptibility gene for CIA, to be the off-target of clozapine. Furthermore, the mRNA expression of HSPA1A-related genes (off-target associated systems) was also found to be differentially expressed in clozapine treated leukemia cell line. Apart from identifying the CIA causal genes we identified several novel candidate genes which could be responsible for agranulocytosis. Proteins related to reactive oxygen clearance system, such as oxidoreductases and glutathione metabolite enzymes, were significantly enriched in the antithesis CPI. This methodology conducted a multi-dimensional analysis of drugs' perturbation to the biological system, investigating both the off-targets and the associated off-systems to explore the molecular basis of an adverse event or the new uses for old drugs. Idiosyncratic drug reactions (IDR) generally cannot be identified until after a drug is taken by a large population, but usually result in restricted use or withdrawal. Clozapine provides the most effective treatment for schizophrenia but its use is limited because of a life-threatening IDR, i.e., the agranulocytosis. A high impact clinical study demonstrated the necessity of moving clozapine from 3rd line to 1st line drug; therefore, intensive research has aimed at identifying genes responsible for clozapine-induced agranulocytosis (CIA). Olanzapine, an analog of clozapine, has much lower incidence of agranulocytosis. Based on this phenomenon, we proposed an in silico methodology termed as antithesis chemical-protein interactome (CPI), which mimics the differences in the drug-protein interactions of the two drugs across a panel of human proteins. e.g., HSPA1A was identified to be targeted by clozapine not olanzapine. Furthermore, the gene expression of the HSPA1A-related gene system was also found up-regulated after clozapine treatment. This approach can examine the system's perturbation in terms of both the off-target and the off-system's interaction with the drug, providing theoretical basis for decoding the adverse drug reactions or the new uses for old drugs.